CPI-818 Clin2 T-cell lymphoma, Clin0 atopic dermatitis, RD/Clin0 autoimmune condition, RD/Clin0 allergy; Mupadolimab Clin1b NSCLC, head & neck cancer
Corvus Pharmaceuticals is taking a multi-pronged approach to treat patients with the most difficult-to-treat diseases. There is much therapeutic need for treating the most advanced stages of diseases in cancer, immune disorders and infectious diseases. Corvus is using a clinical science-driven approach to pioneer precisely targeted medicines for these diseases. Corvus has five proprietary agents in the pipeline, comprising both small molecules and antibodies, with differentiated mechanisms of action, some of which are in Phase 1 clinical trials. This includes CPI-818, an oral, small molecule that inhibits an enzyme expressed predominantly in T cells to treat T cell lymphomas.